Journal article
Vaginally administered PEGylated LIF Antagonist blocked embryo implantation and eliminated non-target effects on bone in mice
E Menkhorst, JG Zhang, NA Sims, PO Morgan, P Soo, IJ Poulton, D Metcalf, E Alexandrou, M Gresle, LA Salamonsen, H Butzkueven, NA Nicola, E Dimitriadis
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2011
Abstract
Female-controlled contraception/HIV prevention is critical to address health issues associated with gender inequality. Therefore, a contraceptive which can be administered in tandem with a microbicide to inhibit sexually transmitted infections, is desirable. Uterine leukemia inhibitory factor (LIF) is obligatory for blastocyst implantation in mice and associated with infertility in women. We aimed to determine whether a PEGylated LIF inhibitor (PEGLA) was an effective contraceptive following vaginal delivery and to identify non-uterine targets of PEGLA in mice. Vaginally-applied 125I-PEGLA accumulated in blood more slowly (30 min vs 10 min) and showed reduced tissue and blood retention (24 h..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the Consortium for Industrial Collaboration in Contraceptive Research Program (CICCR) of the Contraceptive Research and Development Program (CONRAD) Eastern Virginia Medical School (Sub-project CIG-07-116 [ED]), the NHMRC (Australia) (Program grants: 461219 [NN]; 345401 [NAS]; project grants 516730 [JGZ]; 388920 [ED] and fellowships to LAS, NAS and EM), the Lalor Foundation (Postdoctoral Fellowship [EM]) and the Victorian Government's (Australia) Operational Infrastructure Support Program. EM received travel support from The CASS Foundation and the Harold Mitchell Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.